News & Updates
Filter by Specialty:
Show Multimedia Only

Anti-CD20 show promise in multiple sclerosis after alemtuzumab
08 Jul 2024
byStephen Padilla
Treatment with anti-CD20 monoclonal antibodies appears to be a viable option for patients with relapsing-remitting multiple sclerosis (RRMS) who have uncontrolled disease following the use of alemtuzumab therapy, suggests a study presented at EAN 2024.
Anti-CD20 show promise in multiple sclerosis after alemtuzumab
08 Jul 2024
IBS diagnosis tied to lower all-cause, cancer mortality
08 Jul 2024
A diagnosis of irritable bowel syndrome (IBS), a common functional gastrointestinal disorder, appears to contribute to a reduced risk of death, but this association weakens over time, a study has shown.